Thursday, November 12, 2026

Goldman Sachs Forecasts 7-Point ROE Drop for Big Tech as AI Capex Outpaces Revenue

Goldman Sachs published a report on June 12 projecting an average 7 percentage point decline in return on equity for Big Tech's largest companies over the next year. Microsoft, Alphabet, Meta, Amazon, and Apple are driving AI infrastructure spending at a pace that outstrips near-term revenue generation. AI hardware investment cycles typically lag revenue by 18 to 24 months, creating a structural margin pressure window through 2026 and 2027.

LM Salvado
LM Salvado

June 17, 2026

Goldman Sachs Forecasts 7-Point ROE Drop for Big Tech as AI Capex Outpaces Revenue
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Goldman Sachs forecasts a 7 percentage point decline in return on equity for Big Tech's largest companies over the next year, as AI infrastructure spending accelerates faster than revenue can follow.1

The report, published June 12, targets Microsoft, Alphabet, Meta, Amazon, and Apple — the five companies driving the bulk of AI capital expenditure. ROE compression is the projected result as these firms pour capital into data centers, chips, and AI infrastructure before monetization catches up.1

AI hardware and infrastructure investment cycles typically lag revenue generation by 18 to 24 months.1 That gap is the core risk. Companies are committing capital now; returns come later — if at all.

The S&P 500 has returned 9% year-to-date, driven largely by earnings growth.2 That performance assumes Big Tech profitability remains intact. Goldman's forecast challenges that assumption directly.

ROE measures how efficiently a company generates profit from shareholder equity. A 7-point decline is material. A company with 25% ROE dropping to 18% has meaningfully less to return to shareholders or reinvest in the business.

The five companies named represent a significant share of S&P 500 market capitalization. If their ROE falls in line with Goldman's projection, index-level earnings pressure would follow. Current valuations appear to price in continued profitability — not a margin contraction cycle.

The risk is structural. AI capex is not discretionary in the near term. Each company has made public commitments to infrastructure build-outs. Pulling back risks falling behind competitors. Pressing forward risks exactly the margin compression Goldman is warning about.

Revenue from AI — through cloud services, subscriptions, advertising, and enterprise tools — is growing, but not yet at the pace required to offset the capital being deployed. The 18-to-24-month investment-to-revenue lag makes 2026 and 2027 the likely pressure years.1

Investors tracking this trend should monitor quarterly ROE disclosures from Microsoft, Alphabet, Meta, Amazon, and Apple across the next four reporting cycles. A confirmed average decline in the 5 to 9 percentage point range would signal the thesis is materializing as Goldman projects.1

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com